Directa Plus has reported a robust set of interim results with an improved margin and FCF performance, despite lower yoy revenues due to contract delays. H1’23 revenues decreased 17% yoy, but DCTA reported a second successive period of lower FCF burn as the business transitions from its previous R&D focus, to a new commercial strategy focused on end markets where graphene has near-term potential. The period reported did not benefit from any of the well flagged opportunities within Grafysorber, h ....
